神经退行症中的Tamarindus indica果肉:一个多模式的药理学研究
Lutfat A Usman1, Emmanuel O Ajani1, Afolabi C Akinmoladun2
1Department of Biochemistry, Kwara State University, PMB 1530, Malete, 241104 Ilorin Nigeria.
In silico pharmacology
|November 10, 2025
概括
泰玛林印第卡提取物通过减少氧化应激和炎症,对化学诱导的神经元损伤产生神经保护作用. 这种天然化合物有望治疗神经退行性疾病.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
背景情况:
- 神经退行性疾病包括由氧化应激和炎症等因素导致的脑细胞逐渐损伤.
- 富含黄类和类的Tamarindus indica具有潜在的神经保护性质,但尚未完全理解.
- 研究像Tamarindus indica这样的天然化合物为新的神经保护疗法提供了有希望的途径.
研究的目的:
- 通过计算和实验来评估Tamarindus indica水果肉质乙醇提取物的神经保护潜力.
- 为了确定Tamarindus indica中的关键生物活性化合物及其与神经退行性点的相互作用.
- 在化学诱导的神经退行症的体内模型中评估Tamarindus indica提取物的疗效.
主要方法:
- 利用网络药理学,分子对接和分子动力学模拟来分析化合物-目标相互作用.
- 在28天的时间内,在一个由烯酸诱导的神经退行模型中,给大鼠服用Tamarindus indica提取物 (200或400毫克/公斤) 或多尼佩西尔.
- 在体内测量了氧化应激标志物,炎症性细胞因子和乙胆酶活性.
主要成果:
- 计算分析显示,Tamarindus indica的生物活性物质,如原蛋白,对神经保护性标具有强烈的结合亲和力.
- 活体研究表明,提取物增强了抗氧化酶,并减少了脂质过氧化.
- 提取物通过降低对促炎性细胞因子的调节和抑制乙胆酶,显示出抗炎作用.
结论:
- 泰玛林印加提取物通过抗氧化和抗炎机制表现出多目标的神经保护作用.
- 原蛋白被确定为一种关键的生物活性化合物,具有与神经退行性点的显著相互作用.
- 泰马林德 (Tamarindus indica) 是神经退行性疾病的有前途的植物治疗剂,需要进一步研究.
相关概念视频
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180

